LSA
BBIO icon

L & S Advisors’s BridgeBio Pharma BBIO Stock Holding History

L & S Advisors’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$840K Sell
11,273
-4,976
-31% -$349K 0.09% 166
2026
Q1 		$1.21M Sell
16,249
-5,962
-27% -$432K 0.15% 134
2025
Q4 		$1.7M Buy
22,211
+5,318
+31% +$349K 0.16% 160
2025
Q3 		$877K Buy
+16,893
New +$824K 0.08% 179

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

L & S Advisors's BBIO Position: Q2 2026 in Review

L & S Advisors reduced its BridgeBio Pharma (BBIO) stake by 31% in Q2 2026, selling an estimated $349K and leaving 11,273 shares worth $840K. The position accounts for 0.09% of the portfolio, ranked #166.

L & S Advisors first reported a position in BBIO in Q3 2025 and has held it in 4 quarters since. The position peaked at $1.7M in Q4 2025. 475 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • L & S Advisors held 11,273 shares of BridgeBio Pharma worth $840K as of Q2 2026.
  • L & S Advisors sold 4,976 BridgeBio Pharma shares in Q2 2026, an estimated $349K.
  • BridgeBio Pharma made up 0.09% of L & S Advisors's portfolio in Q2 2026, its #166 holding.
  • L & S Advisors first reported a position in BridgeBio Pharma in Q3 2025 and has held it in 4 quarters since.
  • L & S Advisors's BridgeBio Pharma position peaked at $1.7M in Q4 2025.
  • 475 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on L & S Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.